Drug used to reduce blood fats may cut SARS-CoV-2 infection by 70 per cent: Study
The team led by researchers from the University of Birmingham in the UK found that fenofibrate and its active form fenofibric acid can significantly reduce SARS-COV-2 infection, that causes COVID-19, in human cells in the laboratory. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 6, 2021 Category: Pharmaceuticals Source Type: news
FDA Drug Safety Communication: Review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Fenofibric Acid Delayed-Release Capsules (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - April 15, 2019 Category: Drugs & Pharmacology Source Type: news
Alembic Pharma's cholesterol drug gets US FDA nod
The approved product is therapeutically equivalent to the reference listed drug product Trilipix Delayed-Release capsules of Abbvie Inc. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2017 Category: Pharmaceuticals Source Type: news
Fibricor (Fenofibric Acid) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news
Trilipix (Fenofibric Acid Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 7, 2017 Category: Drugs & Pharmacology Source Type: news
fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)
Title: fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 10/31/2016 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - October 31, 2016 Category: Cardiology Source Type: news
Apr 22 Cardiology NewsApr 22 Cardiology News
The FDA’s decision on niacin and fenofibric acid, inappropriate carotid screening, same day discharge PCI, gender differences in testing for CAD, and obesity in adolescents are reviewed this week. theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 22, 2016 Category: Cardiology Tags: Cardiology News Source Type: news
FDA: No More Niacin Combos
(MedPage Today) -- Agency pulls plug on niacin plus statin and niacin fenofibric acid (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 16, 2016 Category: Cardiology Source Type: news
How a reorganized Chapel Hill drug co. will take on the cardiology market
As Pozen (Nasdaq: POZN) turns to the next chapter as a company, it will look to hire a sales force and establish relationships with cardiologists.
This will allow it to first sell the already approved drug Fibricor and set the table to sell Yosprala, which Pozen hopes will soon receive FDA approval.
Since the beginning of June, the company has dropped some bombs. First, founder and longtime CEO John Plachetka retired, then it formed an Irish subsidiary, and finally acquired Canadian specialty pharmaceutical… (Source: bizjournals.com Health Care:Hospitals headlines)
Source: bizjournals.com Health Care:Hospitals headlines - June 16, 2015 Category: Hospital Management Authors: Jason deBruyn Source Type: news
How a reorganized Chapel Hill drug co. will take on the cardiology market
As Pozen (Nasdaq: POZN) turns to the next chapter as a company, it will look to hire a sales force and establish relationships with cardiologists.
This will allow it to first sell the already approved drug Fibricor and set the table to sell Yosprala, which Pozen hopes will soon receive FDA approval.
Since the beginning of June, the company has dropped some bombs. First, founder and longtime CEO John Plachetka retired, then it formed an Irish subsidiary, and finally acquired Canadian specialty pharmaceutical… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 16, 2015 Category: Biotechnology Authors: Jason deBruyn Source Type: news
Darryl Sleep
Senior Vice President, Head of Clinical Science and Asset Strategy for the Cardiovascular and Metabolic Therapeutic Area Unit With extensive global clinical and industry experience across multiple therapeutic areas Darryl Sleep, M.D. is Senior Vice President, Head of Clinical Science and Asset Strategy for the Cardiovascular and Metabolic (CVM) Therapeutic Area Unit (TAU) at Takeda Pharmaceuticals. He leads the clinical science group as well as the program leaders within the CVM TAU that covers a wide pipeline portfolio including programs in the cardiovascular, diabetes, obesity, renal, and respiratory areas.
Dr. Sleep j...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)
Title: fenofibrate (Antara, Fenoglide, Fibricor, Lipofen, Lofibra, Tricor, Triglide, Trilipix)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 11/11/2014 12:00:00 AM (Source: MedicineNet Cholesterol General)
Source: MedicineNet Cholesterol General - November 11, 2014 Category: Cardiology Source Type: news
Lupin launches generic Fenofibric Acid capsules in US market
Lupin said its US arm has launched generic Fenofibric Acid capsules used for reducing cholesterol and fatty acids in the blood in the American market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 6, 2013 Category: Pharmaceuticals Source Type: news
